Le Lézard
Classified in: Health, Science and technology

Lithuanian Biotech Pioneer 'Nando' Embarks on Global Expansion With New Management Team and Innovative Production Line


"Nando", a leading Lithuanian-owned biotechnology company known for its groundbreaking work in developing microbiological products for agriculture, that helped to save up to 50M on fertilisers, announces a significant bolstering of its management team and an ambitious expansion of its biotechnological production line. This move is set to position "Nando" not just as a leader in Lithuania but as a formidable player on the international stage.

KAUNAS, LITHUANIA / ACCESSWIRE / May 7, 2024 / In a strategic enhancement of its management team, "Nando" welcomes four seasoned professionals, each bringing a wealth of experience from reputable organizations. Gytis Kubilius, with a solid background in management at "SEB" and "Citadele" banks; Mindaugas Navickas, previously International Sales Manager at "Teltonika Networks"; Ar?nas Jusas, former General Manager at "Timac AGRO"; and Giedr? Mockien?, who served as HR Manager at UAB "Yara", are now integral parts of "Nando's" leadership, aiming to spearhead ambitious development projects.

To cater to the surging demand for microbiological alternatives to mineral fertilizers and plant protection products, "Nando" has invested about €3 million in a unique biotechnology line. This investment boosts production volume, enhances productivity, and ensures competitive pricing to meet the escalating market demand. With a technology that is currently patent-pending, "Nando" exports to over 20 countries, including Great Britain, Ukraine, Estonia, Kazakhstan, Latvia, Poland, Romania and beyond.

Justinas Taru?ka, CEO of "Nando", stated, "Our main goal is to feature a highly automated biotechnological production line. This will not only elevate the agro-biotechnology sector's value in Lithuania but also accelerate sustainable and economically viable agricultural technologies across Europe and other continents." The new production line is renowned for its unique microorganism purification technology, a rarity in the entire Baltic region. It promises an efficient production of stable, high-yield microbiological products in powder form, a technology with limited competition.

The inclusion of new management members, with their extensive international experience, underscores "Nando's" commitment to employee development and its focus on penetrating foreign markets, including Europe, North and South America, Asian and Africa countries. This strategic move coincides with the launch of the new production line for microbiological products.

Founded in 2007, "Nando" stands at the forefront of the biotech industry, developing and manufacturing microbiological products and chemical additives for agriculture. With one of Northern Europe's leading R&D centers and partnerships with global research institutions, "Nando" has introduced over 50 innovative products, vital to the agro, livestock. Currently, the company is intensifying its export activities, with operations spanning over 20 countries in Europe, North and South America, Asian and Africa. The "Nando Group" proudly employs more than 50 professionals dedicated to advancing global biotechnology solutions.

Contact Information:

Milda Gauliene
Marketing specialist
[email protected]
+37066475297

SOURCE: Nando

.

View the original press release on newswire.com.


These press releases may also interest you

18 mai 2024
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

18 mai 2024
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

18 mai 2024
"Maximizing customer retention and expansion is more important than ever for B2B SaaS companies," said Steven Forth, CEO of Ibbaka. "Our...

18 mai 2024
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...

18 mai 2024
Mirum Pharmaceuticals, Inc. today announced data presented during the 56th European Society for Paediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting which took place this week in Milan, Italy. Data from LIVMARLI®...

18 mai 2024
After tens of thousands of NYC children were turned away from "Summer Rising," New York City's popular, free summer enrichment program, Brains & Motion launched a campaign offering camps at NYU for a small fraction of the up-to-$1400 per week price...



News published on and distributed by: